Page 1 of 1 Quantitative Equity Report | Release: 28 Dec 2015, 23:01, GMT-06:00 | Reporting Currency: EUR | Trading Currency: EUR Neuron Bio SA NEU Last Close 28 Dec 2015 Quantitative Fair Value Est 28 Dec 2015 Market Cap 28 Dec 2015 Sector Industry 1.54 1.85 10.6 Mil d Healthcare Biotechnology Neuron Bio SA, through its divisions, is engaged in the development of bio solutions for the pharmaceutical and agrofood industries. Country of Domicile ESP Spain Price Versus Quantitative Fair Value 2011 2012 2013 2014 2015 2016 Sales/Share Forecast Range Forcasted Price Dividend Split Quantitative Fair Value Estimate 10 Total Return Quantitative Scores 8 Scores Momentum: — Standard Deviation: 85.23 Liquidity: Medium All Rel Sector Rel Country Quantitative Moat None Valuation Undervalued Quantitative Uncertainty Very High Financial Health Moderate 30 82 43 13 37 68 41 5 6 25 83 28 3 4 1.29 52-Wk 3.28 0.64 5-Yr 4.16 2 NEU d ESP Undervalued Fairly Valued Overvalued Source: Morningstar Equity Research Valuation Sector Median Country Median — — — — — — — — 0.88 27.5 12.4 18.6 28.0 1.41 3.3 4.0 0.91 17.1 13.2 8.8 14.6 2.74 1.5 1.1 Current 5-Yr Avg Sector Median Country Median 12.5 6.7 306.4 Current 5-Yr Avg Price/Quant Fair Value Price/Earnings Forward P/E Price/Cash Flow Price/Free Cash Flow Dividend Yield % Price/Book Price/Sales 0.83 — — — — — 1.2 131.7 Profitability Return on Equity % Return on Assets % Revenue/Employee (K) -12.3 -4.2 3.3 -10.1 -3.8 6.4 Quantitative Moat -30.0 -16.0 14.3 -3.4 -35.4 -50.9 48.4 52.1 -33.0 -32.9 — -14.1 38.8 — 104.2 51.0 — 41.8 54.1 — -19.8 59.2 — -12.9 131.7 Total Return % +/– Market (Morningstar World Index) Dividend Yield % Price/Earnings Price/Revenue Morningstar RatingQ QQQQQ QQQQ QQQ QQ Q Financials (Fiscal Year in K) Revenue % Change 2010 2011 2012 2013 2014 TTM 250 -47.9 418 67.2 200 -52.1 53 -73.5 157 196.7 76 -51.6 -1,617 — -404 -2,121 — -631 -2,020 — 99 -1,924 — -1,139 -2,468 — -2,552 -2,523 — -1,190 10.5 2.9 275.9 -3,046 -2,092 -5,138 -2,054.1 -3,567 -2,933 -6,500 -1,553.8 -1,172 -3,487 -4,659 -2,326.6 54 -4,032 -3,978 -7,495.1 -2,769 -688 -3,457 -2,195.4 -2,769 -688 -3,457 -4,532.8 Score 100 -0.09 -231.1 -0.81 -0.14 — -0.91 0.02 — -1.09 -0.26 -1,220.6 -0.46 -0.37 — -0.84 -0.12 — -0.35 EPS % Change Free Cash Flow/Share — 2.39 4,625 — 2.21 4,263 — 2.38 4,391 — 2.01 6,881 — 1.64 — — 1.17 6,881 Dividends/Share Book Value/Share Shares Outstanding (K) -4.4 -2.5 -161.3 0.02 1.7 -6.7 -3.2 -150.9 0.02 2.8 1.1 0.4 49.3 0.01 2.4 -11.8 -4.5 -2,145.9 0.00 2.9 -27.7 -9.0 -1,620.6 0.01 3.3 -12.3 -4.2 -1,560.4 0.00 3.5 Profitability Return on Equity % Return on Assets % Net Margin % Asset Turnover Financial Leverage 735.5 -646.5 1,874 503.2 -507.1 2,433 526.7 -1,008.9 1,257 1,589.6 -3,624.6 1,112 361.0 -1,567.3 9,989 741.4 -3,308.3 — Gross Margin % Operating Margin % Long-Term Debt 11,196 0.1 7,569 0.1 10,148 0.0 9,149 0.0 9,289 0.0 8,080 0.0 80 Operating Income % Change Net Income Operating Cash Flow Capital Spending Free Cash Flow % Sales 60 40 20 0 2008 2009 2010 2011 2012 2013 2014 Financial Health Current 5-Yr Avg Distance to Default Solvency Score Assets/Equity Long-Term Debt/Equity 0.2 896.5 3.3 1.1 — — 2.6 0.4 2015 Sector Median Country Median 0.6 501.0 1.4 0.1 0.6 628.2 2.7 0.3 Growth Per Share Revenue % Operating Income % Earnings % Dividends % Book Value % Stock Total Return % 1-Year 3-Year 5-Year 10-Year 196.7 — — — -35.2 -24.5 -27.8 — — — -14.3 -13.7 -20.0 — — — -9.2 -11.1 — — — — — — Semi-Annual Revenue & EPS Revenue (K) Mar Jun 2015 — 69.7 2014 — 150.9 2013 — 21.1 2012 — 95.4 Earnings Per Share () 2015 — 0.10 2014 — -0.15 2013 — -0.29 2012 — -0.31 Total Equity Fixed Asset Turns Revenue Growth Year On Year % Sep — — — — Dec — 6.6 32.0 104.9 Total — 157.5 53.1 200.3 — — — — — -0.22 0.03 0.33 — -0.37 -0.26 0.02 615.2 192.6 0.4 -41.7 2011 2012 -58.8 -77.9 2013 © Morningstar 2015. All Rights Reserved. Unless otherwise provided in a separate agreement, you may use this report only in the country in which its original distributor is based. The information, data, analyses and opinions presented herein do not constitute investment advice; are provided solely for informational purposes and therefore is not an offer to buy or sell a security; are not warranted to be correct, complete or accurate; and are subject to change without notice. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information herein may not be reproduced, in any manner without the prior written consent of Morningstar. Please see important disclosures at the end of this report. -69.5 -79.5 2014 -53.8 2015 ® ß
© Copyright 2024